- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MRK
Recent news which mentions MRK
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
From Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
From Benzinga
A Closer Look at 8 Analyst Recommendations For Merck & Co
September 16, 2024
Tickers
MRK
From Benzinga
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
September 16, 2024
From Benzinga
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
September 13, 2024
From Benzinga
Is Summit Therapeutics a Buy Now?
September 10, 2024
From Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
From Motley Fool
From Benzinga
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
September 09, 2024
From Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
From Benzinga
3 No-Brainer Dividend Stocks to Buy in September
September 08, 2024
From Motley Fool
What's Going On With Merck Shares Thursday?
September 05, 2024
From Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
September 05, 2024
From Motley Fool
The Smartest Dividend Stocks to Buy With $5,000 Right Now
September 05, 2024
From Motley Fool
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
September 03, 2024
From Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 03, 2024
From Benzinga
2 Dividend Stocks You Can Safely Hold Through a Recession
September 02, 2024
From Motley Fool
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
August 29, 2024
From Benzinga
From Benzinga
12 Dividend Stocks to Earn Income Every Month
August 28, 2024
From Motley Fool
From Benzinga
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
August 27, 2024
From Motley Fool
Merck & Co's Options: A Look at What the Big Money is Thinking
August 26, 2024
Tickers
MRK
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.